CombinatoRx , Incorporated

CombinatoRx, a privately held pharmaceutical company, is creating new combination medicines that attack disease on multiple fronts. The company has an impressive clinical and preclinical pipeline of novel agents, including treatments in development for cancer and rheumatoid arthritis, and has ongoing research in respiratory, metabolic, and infectious diseases. CombinatoRx invented the industry's first combination drug discovery platform to generate new medicines, based upon new insights into disease networks, in a broad range of therapeutic areas. Founded in 2000 by leading scientists from Harvard and MIT, the company has raised $90M in venture capital and is executing on its business strategy to rapidly build and commercialize a portfolio of breakthrough products. ( www.combinatorx.com )